Lindsay B. Kilburn

Mar 11, 2024 | nature.com | Lindsay B. Kilburn |Dong-Anh Khuong-Quang |Jordan Hansford |Pablo Hernáiz Driever |Simon T. Bailey |David Ziegler | +10 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02668-y, published online 17 November 2023. In the version of the article initially published, in the third paragraph of the “RAPNO criteria (secondary endpoints)” section, the text now reading “Thirteen (17.1%) patients initially had a best overall response of PD…” originally read “Thirty-one patients initially had PD…”. This has been corrected in the HTML and PDF versions of the article.

Nov 17, 2023 | nature.com | Lindsay B. Kilburn |Dong-Anh Khuong-Quang |Jordan Hansford |Pablo Hernáiz Driever |Simon T. Bailey |David Ziegler | +10 more

AbstractBRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial investigated the efficacy of the oral, selective, central nervous system–penetrant, type II RAF inhibitor tovorafenib (420 mg m−2 once weekly; 600 mg maximum) in patients with BRAF-altered, relapsed/refractory pLGG.